Navari R - Search Results

1

Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles.

Navari R, Binder G, Molasiotis A, Herrstedt J, Roeland EJ, Ruddy KJ, LeBlanc TW, Kloth DD, Klute KA, Papademetriou E, Schmerold L, Schwartzberg L. Navari R, et al. Oncologist. 2023 Mar 17;28(3):208-213. doi: 10.1093/oncolo/oyac240. Oncologist. 2023. PMID: 36527702 Free PMC article.

2

The current status of the use of palonosetron.

Navari R. Navari R. Expert Opin Pharmacother. 2013 Jul;14(10):1281-4. doi: 10.1517/14656566.2013.799141. Epub 2013 May 7. Expert Opin Pharmacother. 2013. PMID: 23647207

3

Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.

Navari RM. Navari RM. Future Oncol. 2006 Oct;2(5):591-602. doi: 10.2217/14796694.2.5.591. Future Oncol. 2006. PMID: 17026451 Review.

4

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ. Navari RM, et al. N Engl J Med. 1999 Jan 21;340(3):190-5. doi: 10.1056/NEJM199901213400304. N Engl J Med. 1999. PMID: 9917226 Free article. Clinical Trial.

5

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

Pater JL, Lofters WS, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. Pater JL, et al. Among authors: navari r. Ann Oncol. 1997 Feb;8(2):181-5. doi: 10.1023/a:1008247830641. Ann Oncol. 1997. PMID: 9093728 Free article. Clinical Trial.

6

Glucose metabolism in advanced lung cancer patients.

Richards EW, Long CL, Nelson KM, Pinkston JA, Navari RM, Geiger JW, Gandy RE, Blakemore WS. Richards EW, et al. Among authors: navari rm. Nutrition. 1992 Jul-Aug;8(4):245-51. Nutrition. 1992. PMID: 1498456

7

Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists.

Navari RM. Navari RM. Support Cancer Ther. 2004 Jan 1;1(2):89-96. doi: 10.3816/SCT.2004.n.002. Support Cancer Ther. 2004. PMID: 18628185

8

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.

Kris MG, Pendergrass KB, Navari RM, Grote TH, Nelson AM, Thomas V, Ferguson BB, Allman DS, Pizzo BA, Baker TW, Fernando IJ, Chernoff SB. Kris MG, et al. Among authors: navari rm. J Clin Oncol. 1997 May;15(5):2135-8. doi: 10.1200/JCO.1997.15.5.2135. J Clin Oncol. 1997. PMID: 9164228 Clinical Trial.

9

Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.

Santen RJ, Demers LM, Lynch J, Harvey H, Lipton A, Mulagha M, Hanagan J, Garber JE, Henderson IC, Navari RM, et al. Santen RJ, et al. Among authors: navari rm. J Clin Endocrinol Metab. 1991 Jul;73(1):99-106. doi: 10.1210/jcem-73-1-99. J Clin Endocrinol Metab. 1991. PMID: 1646219

10

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.

Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, Anthony L, Khojasteh A, Tapazoglou E, Benedict C, Hahne W. Hesketh P, et al. Among authors: navari r. J Clin Oncol. 1996 Aug;14(8):2242-9. doi: 10.1200/JCO.1996.14.8.2242. J Clin Oncol. 1996. PMID: 8708713 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

145 results

Search Page